BCM
IMUC

Bridgeway Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Bridgeway Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,750
Closed -$62K – 1591
2014
Q3 		$62K Hold
1,750
– – ﹤0.01% 1449
2014
Q2 		$78K Hold
1,750
– – ﹤0.01% 1410
2014
Q1 		$85K Hold
1,750
– – ﹤0.01% 1391
2013
Q4 		$65K Sell
1,750
-2,625
-60% -$249K ﹤0.01% 1370
2013
Q3 		$450K Hold
4,375
– – 0.02% 1086
2013
Q2 		$340K Buy
+4,375
New +$419K 0.01% 1118

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bridgeway Capital Management's IMUC Position: Q4 2014 in Review

Bridgeway Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2014, closing a stake of 1,750 shares — an estimated $62K sold.

Bridgeway Capital Management first reported a position in IMUC in Q2 2013 and held it in 6 quarters. The position peaked at $450K in Q3 2013. 31 funds tracked by Wall St. Rank hold IMUC as of Q4 2014.

  • Bridgeway Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2014 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,750 ImmunoCellular Therapeutics, Ltd. shares in Q4 2014, an estimated $62K.
  • Bridgeway Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 6 quarters.
  • Bridgeway Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $450K in Q3 2013.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2014.

Based on Bridgeway Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.